Zhejiang Hengtong Holding (600226.SH) plans to acquire a 40% stake in Chongqing Aolong Bioproducts Co., Ltd. for 274 million yuan.

Zhejiang Hengtong Holding (600226.SH) announced that the company plans to use its own funds or self-raised funds of 274 million yuan to acquire 40% equity of Chongqing Aolong Bioproducts Co., Ltd. (referred to as "Aolong Bioproducts") held by Huapai Biotechnology (Group) Co., Ltd. After the completion of this acquisition, the company will hold a 40% stake in Aolong Bioproducts, which will not be included in the company's consolidation scope. The target company specializes in ruminant animal vaccines, with a leading position in the domestic market in the field of cattle and sheep vaccines. This transaction will enhance the company's product layout in the biotechnology field, providing customers with a comprehensive product matrix covering animal vaccines, animal drugs, feed additives, and other products. In addition, the company can achieve channel sharing and research and development cooperation with the target company, build core technological barriers, and further enhance the company's market share.